阿瓦洛治疗机构任命珍妮弗·莱利为首席战略干事,领导增长举措。 Avalo Therapeutics appoints Jennifer Riley as Chief Strategy Officer to lead growth initiatives.

一家专注于免疫障碍的生物技术公司Avalo治疗公司已任命Jennifer Riley为首席战略干事。 Avalo Therapeutics, a biotech firm focused on immune disorders, has appointed Jennifer Riley as its Chief Strategy Officer. 从1月1日起,Riley将领导该公司的战略和产品管道规划,目的是推动增长和创新。 Effective January 1, Riley will lead the company’s strategy and product pipeline planning, aiming to drive growth and innovation. Riley拥有20多年的生物技术和制药经验,以前领导Northbrook咨询公司,并在Biogen担任高级职务。 With over 20 years of experience in biotech and pharmaceuticals, Riley previously led Northbrook Consulting and held senior roles at Biogen. Avalo的股票在最近的交易中略有下降。 Avalo’s stock has slightly declined in recent trading.